Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...

Dosage Regimen: Multiple Oral Dosage

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Rational Dosage Regimen: Maintenance Dose and Loading Dose

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Russian experts' clinical guidelines for acute myeloid leukemia treatment in patients less than 60 years of age].

Terapevticheskii arkhiv·2014

Same author

[Monitoring of intracranial pressure and cerebral compliance in patients with hemispheric non-traumatic hemorrhages].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2013

Same author

[The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].

Terapevticheskii arkhiv·2012

Same author

[Tissue equivalent for the closure of extended urethral defects].

Vestnik Rossiiskoi akademii meditsinskikh nauk·2011

Same author

[First results of Ph-negative acute lymphoblastic leukemia therapy of adults according to the protocol of Research Group of Russian Hematological Centers ALL-2009].

Terapevticheskii arkhiv·2011

Same author

[Toxicity of different treatment protocols for acute myeloid leukemias in adults: the results of four Russian multicenter studies].

Terapevticheskii arkhiv·2010

Search research articles

Related Experiment Videos

[Experience with velcade administration in multiple myeloma].

T S Kaporskaia, I V Kiselev

Terapevticheskii Arkhiv

|December 25, 2008

Summary

Velcade therapy showed a 55.9% overall response rate in patients with progressive or resistant multiple myeloma (MM) who failed prior treatments. This indicates Velcade

Area of Science:

Hematology
Oncology
Pharmacology

Context:

Multiple myeloma (MM) is a progressive plasma cell malignancy.
Treatment resistance and progression are significant challenges in MM management.
Standard therapies often fail in advanced or relapsed MM cases.

Purpose:

To evaluate the efficacy of Velcade (bortezomib) therapy in patients with progressive or resistant multiple myeloma.
To assess treatment response rates and disease stabilization with Velcade.

Summary:

Velcade therapy was administered to 36 patients with progressive or resistant multiple myeloma after failure of standard second-line treatments.
An overall response rate of 55.9% was observed, with complete, partial, and minimal responses achieved in several patients.

Related Experiment Videos

Velcade demonstrated disease stabilization in some patients, with a median follow-up of 8 months for this subgroup.

Impact:

Velcade offers a viable treatment option for multiple myeloma patients refractory to conventional therapies.
The study contributes to understanding Velcade's role in managing advanced multiple myeloma.
Findings support Velcade's inclusion in treatment protocols for challenging MM cases.